BioSpace News Archive

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that 100 years of clinical evidence supporting the use of proenzymes as a new therapeutic approach to treat cancer can be considered ‘compelling’.

According to Vision Research Reports, the U.S. office-based labs market size was estimated at around USD 9.7 billion in 2021 and it is projected to hit around USD 18.5 billion by 2030, growing at a CAGR of 7.44% from 2022 to 2030.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the principal design work of a PCR test for the monkeypox virus currently exhibiting a multi-country outbreak.

According to Vision Research Reports, the Europe medical foods market was surpassed at USD 5.7 billion in 2021 and is expected to hit around USD 7.4 billion by 2030, growing at a CAGR of 2.94% from 2022 to 2030.

According to QY Research Medical, the cord blood banking services market size was valued at US$ 1.3 billion in 2020, and is projected to reach US$ 4.5 billion by 2030, growing at a CAGR of 13.6% from 2021 to 2030.

According to QY Research Medical, the arthroscopy devices market size was valued at $18.0 billion in 2020, and is projected to reach $41.9 billion by 2030, growing at a CAGR of 8.8% from 2021 to 2030.

According to QY Research Medical, the organ-on-chip market size was surpassed at $103.44 million in 2020, and is expected to reach $1.6 billion by 2030, growing at a CAGR of 31.5% from 2021 to 2030.

ManaMed (ManaMed.com) is proud to announce the U.S. Food and Drug Administration (FDA) approval for the ManaSport™ ultrasound therapy Class II device.

EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting.

Hesperos Inc., leaders in Human-on-a-Chip®, in vitro systems, announced the recent appointment of a new Chief Executive Officer, Dr. James Kronauge, effective April 1, 2022.